A carregar...
Economic Benefits of Switching From Intravenous to Subcutaneous Epoetin Alfa for the Management of Anemia in Hemodialysis Patients
BACKGROUND: Erythropoiesis-stimulating agents including epoetin alfa have been a mainstay of anemia management in patients with chronic kidney disease. Although the standard practice has been to administer epoetin alfa to patients on hemodialysis (HD) intravenously (IV), subcutaneous (SQ) epoetin al...
Na minha lista:
| Publicado no: | Can J Kidney Health Dis |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7273547/ https://ncbi.nlm.nih.gov/pubmed/32547774 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2054358120927532 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|